Locteron Improves HCV Therapy
Share
Follow Us
Biolex Announces Presentation at EASL of Interim Results From EMPOWER Phase 2b Study of Locteron® in Chronic Hepatitis C
Locteron Dosed Once Every Two Weeks Demonstrated a Comparable Reduction in Viral Load Compared to Once-Weekly Standard of Care With 57% Less Flu-Like Adverse Events
PITTSBORO, NC–(Marketwire – April 16, 2010) – Biolex Therapeutics, Inc. announced that interim results from EMPOWER, a prospectively designed analysis of results from two Phase 2b trials of Locteron®, were presented yesterday in a late-breaker session at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. Locteron, controlled-release interferon alpha 2b, is designed to improve patient care by providing a more convenient once-every-two week dosing schedule and by reducing the flu-like symptoms associated with pegylated interferons, the current standard of care. In the EMPOWER study, the 480 µg dose of Locteron demonstrated viral kinetics and response rates that were comparable to the PEG-Intron® control while also achieving a 57% reduction in flu-like adverse events.
Continue reading this entire article:
http://www.marketwire.com/press-release/Biolex-Announces-Presentation-EASL-Interim-Results-From-EMPOWER-Phase-2b-Study-Locteron-1148840.htm
